PharmaTher Sells Ketamine ANDA for Up to $25M, Maintains Market Exposure
PharmaTher Holdings Ltd. has signed a definitive Asset Purchase Agreement for the sale of its ANDA #217858 for Ketamine Hydrochloride Injection USP to a well-established global pharmaceutical company specializing in sterile injectables and complex generics. The buyer is a credible manufacturer with multiple FDA approvals and an active portfolio of over 40 approved ANDAs in the globe. Under the agreement, PharmaTher will receive a confidential upfront cash payment upon closing, along with potential milestone payments based on cumulative sales thresholds and ongoing profit-sharing for seven years following the first commercial sale. These payments could total over US$25 million. The deal is subject to customary closing conditions and is expected to close in the near term. The agreement allows PharmaTher to maintain exposure to the global ketamine market and focus on advancing next-generation ketamine programs. It also enables the company to participate in the potential long-term commercial success of the ANDA. While the name of the purchasing company remains confidential, it is known to be a well-established global pharmaceutical company with FDA-approved manufacturing capabilities. This deal signifies a significant step for PharmaTher in its strategic commercial real estate plans.
Read also:
- State Supreme Court Rules in Favor of Hogg Hummock Residents, Referendum on Zoning Change to Proceed
- Germany's Coalition Explores Social Security Reforms Amid Record Spending
- Hundreds of Steelworkers and Metalworkers Protest in Duisburg for 4% Pay Hike
- chaos unveiled on Clowning Street: week 63's antics from 'Two-Tier Keir' and his chaotic Labour Circus
